Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 156

Related Citations for PubMed (Select 12816862)

1.

Rituximab in relapsed or refractory hairy cell leukemia.

Thomas DA, O'Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ, Cortes J, Kantarjian HM.

Blood. 2003 Dec 1;102(12):3906-11. Epub 2003 Jun 19.

2.

Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia.

Nieva J, Bethel K, Saven A.

Blood. 2003 Aug 1;102(3):810-3. Epub 2003 Mar 27.

3.

[Complete remission after Rituximab treatment in refractory hairy cell leukemia].

Petruskevicius I, Bukh A, Mertz H, Johnsen HE.

Ugeskr Laeger. 2008 Jun 23;170(26-32):2350. Danish.

PMID:
18570771
4.

Rituximab as treatment for minimal residual disease in hairy cell leukaemia.

Cervetti G, Galimberti S, Andreazzoli F, Fazzi R, Cecconi N, Caracciolo F, Petrini M.

Eur J Haematol. 2004 Dec;73(6):412-7.

PMID:
15522063
5.

[Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].

Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.

Ai Zheng. 2006 Apr;25(4):486-9. Chinese.

PMID:
16613686
6.

The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia.

Else M, Osuji N, Forconi F, Dearden C, Del Giudice I, Matutes E, Wotherspoon A, Lauria F, Catovsky D.

Cancer. 2007 Nov 15;110(10):2240-7.

7.

Successful induction of long-term remission using rituximab in a patient with refractory hairy cell leukemia-Japanese variant.

Imamura T, Ohtsuka E, Ogata M, Oka F, Kashima K, Kikuchi H, Nasu M.

Int J Hematol. 2004 Dec;80(5):432-4.

PMID:
15646655
8.

Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia.

Lauria F, Lenoci M, Annino L, Raspadori D, Marotta G, Bocchia M, Forconi F, Gentili S, La Manda M, Marconcini S, Tozzi M, Baldini L, Zinzani PL, Foà R.

Haematologica. 2001 Oct;86(10):1046-50.

9.

Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.

Medeot M, Zaja F, Vianelli N, Battista M, Baccarani M, Patriarca F, Soldano F, Isola M, De Luca S, Fanin R.

Eur J Haematol. 2008 Sep;81(3):165-9. doi: 10.1111/j.1600-0609.2008.01100.x. Epub 2008 May 27.

PMID:
18510702
10.

Cladribine in hairy cell leukemia.

Belani R, Saven A.

Hematol Oncol Clin North Am. 2006 Oct;20(5):1109-23. Review.

PMID:
16990111
11.

A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation.

Olivieri A, Lucesole M, Capelli D, Gini G, Montanari M, Candela M, Troiani E, Scortechini I, Poloni A, Leoni P.

Biol Blood Marrow Transplant. 2005 Aug;11(8):627-36.

PMID:
16041313
12.

Eradication of minimal residual disease in hairy cell leukemia.

Ravandi F, Jorgensen JL, O'Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM.

Blood. 2006 Jun 15;107(12):4658-62. Epub 2006 Feb 23.

13.

Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience.

Bienert M, Reisinger I, Srock S, Humplik BI, Reim C, Kroessin T, Avril N, Pezzutto A, Munz DL.

Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1225-33. Epub 2005 Jun 4.

PMID:
15937686
14.

Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.

Johnston JB, Eisenhauer E, Wainman N, Corbett WE, Zaentz SD, Daeninck PJ.

Semin Oncol. 2000 Apr;27(2 Suppl 5):32-6.

PMID:
10877049
15.

Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.

Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZ, Johnson SA, O'Connor NT, Haynes A, Osuji N, Forconi F, Lauria F, Catovsky D.

Br J Haematol. 2009 Jun;145(6):733-40. doi: 10.1111/j.1365-2141.2009.07668.x. Epub 2009 Mar 29.

PMID:
19344416
16.

Hairy-cell leukemia and alpha-interferon treatment: long-term responders.

Zinzani PL, Lauria F, Salvucci M, Rondelli D, Raspadori D, Bendandi M, Magagnoli M, Tura S.

Haematologica. 1997 Mar-Apr;82(2):152-5.

17.

Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.

Jermann M, Jost LM, Taverna Ch, Jacky E, Honegger HP, Betticher DC, Egli F, Kroner T, Stahel RA.

Ann Oncol. 2004 Mar;15(3):511-6.

18.

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.

Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group).

Haematologica. 2008 Dec;93(12):1829-36. doi: 10.3324/haematol.13440. Epub 2008 Oct 22.

19.

Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial.

Ekstrand BC, Lucas JB, Horwitz SM, Fan Z, Breslin S, Hoppe RT, Natkunam Y, Bartlett NL, Horning SJ.

Blood. 2003 Jun 1;101(11):4285-9. Epub 2003 Feb 13.

20.

High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.

Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E.

Leuk Lymphoma. 2006 Aug;47(8):1545-52.

PMID:
16966265
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk